We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

208 hedge funds and large institutions have $3.76B invested in Pacira BioSciences in 2014 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 83 increasing their positions, 69 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 18

20% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 69

9% more funds holding

Funds holding: 191 → 208 (+17)

8% more capital invested

Capital invested by funds: $3.48B → $3.76B (+$281M)

18% less funds holding in top 10

Funds holding in top 10: 11 → 9 (-2)

18% less call options, than puts

Call options by funds: $21.8M | Put options by funds: $26.7M

Holders
208
Holders Change
+17
Holders Change %
+8.9%
% of All Funds
6.04%
Holding in Top 10
9
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-18.18%
% of All Funds
0.26%
New
36
Increased
83
Reduced
69
Closed
18
Calls
$21.8M
Puts
$26.7M
Net Calls
-$4.92M
Net Calls Change
-$3.87M

Top Buyers

Rank Fund Capital Flow
1
MCM
Marsico Capital Management
Colorado
+$41.9M
2
RIM
RS Investment Management
California
+$39.4M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$39.3M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$36.9M
5
O
OrbiMed
New York
+$23.1M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$51.7M
2
VAM
Visium Asset Management
New York
-$40.3M
3
DCM
Daruma Capital Management
New York
-$30.9M
4
Jennison Associates
Jennison Associates
New York
-$26.3M
5
Millennium Management
Millennium Management
New York
-$25.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
WMSA
126
Weiss Multi-Strategy Advisers
New York
$1.16M -$292K -3,000 -20%
M&T Bank
127
M&T Bank
New York
$1.14M +$1.14M +11,719 New
SIM
128
Spark Investment Management
New York
$1.1M +$1.11M +11,400 New
GPCM
129
Granite Point Capital Management
Massachusetts
$969K – – –
Stifel Financial
130
Stifel Financial
Missouri
$947K -$328K -3,372 -26%
Tudor Investment Corp
131
Tudor Investment Corp
Connecticut
$881K +$885K +9,094 New
WIC
132
Woodmont Investment Counsel
Tennessee
$818K +$263K +2,700 +47%
MAM
133
Martingale Asset Management
Massachusetts
$796K +$798K +8,204 New
QIM
134
Quest Investment Management
Oregon
$776K +$259K +2,658 +50%
Jane Street
135
Jane Street
New York
$774K -$769K -7,907 -50%
PP
136
PDT Partners
New York
$756K – – –
FSA
137
Franklin Street Advisors
North Carolina
$754K – – –
Principal Financial Group
138
Principal Financial Group
Iowa
$737K +$17.5K +180 +2%
NSAM
139
North Star Asset Management
Wisconsin
$708K +$224K +2,300 +46%
KBC Group
140
KBC Group
Belgium
$701K -$3.84M -39,512 -85%
GC
141
Globeflex Capital
California
$688K +$691K +7,100 New
GAM
142
Gotham Asset Management
New York
$673K -$247K -2,540 -27%
HFS
143
HL Financial Services
Kentucky
$666K -$6.52K -67 -1%
TFCP
144
Twin Focus Capital Partners
Massachusetts
$661K -$331K -3,407 -33%
FAM
145
Fortaleza Asset Management
Illinois
$650K +$652K +6,705 New
EWM
146
Evercore Wealth Management
New York
$641K -$581K -5,973 -47%
SO
147
STRS Ohio
Ohio
$620K +$87.6K +900 +16%
T
148
TradeWorx
New Jersey
$620K +$623K +6,402 New
SI
149
Standard Investments
New York
$556K – – –
CIM
150
CenturyLink Investment Management
Colorado
$535K +$537K +5,523 New
4 5
6
7 8

PCRX Hedge Fund Activity: Q3 2014 in Review

208 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q3 2014, worth a combined $3.76B — up 8.1% from $3.48B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new PCRX positions and 18 closed out — a net gain of 18 holders — while 83 added to existing stakes and 69 trimmed.

The largest buyer was Marsico Capital Management, adding an estimated $41.9M. The largest seller was Wellington Management Group, cutting an estimated $51.7M.

  • 208 institutional investors held Pacira BioSciences (PCRX) as of Q3 2014, up from 191 in Q2 2014.
  • Funds reported $3.76B of Pacira BioSciences stock for Q3 2014, up 8.1% quarter-over-quarter.
  • 36 funds opened new Pacira BioSciences positions in Q3 2014 and 18 closed out, a net change of +18 holders.
  • The largest Pacira BioSciences buyer in Q3 2014 was Marsico Capital Management, an estimated $41.9M added.
  • The largest Pacira BioSciences seller in Q3 2014 was Wellington Management Group, an estimated $51.7M sold.

Based on aggregated 13F filings for Q3 2014.